NEVVI Medicare utilization intelligence
Compare this code with others
Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS

Jump to the result views

Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg HCPCS · Treatment
Classification Treatment › Injections and Infusions (nononcologic) › Injection - Immunomodulator (CMS RBCS)
First observed 2020
National scale 256,581 services · est. ▼ 37.8% YoY · 1,070 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 131,406 observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief Q5115
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

Included in Explore. Part of a Deep Dive.
Continue from here

Browse Medicare billing by specialty →